Table 2. Patients with at least one CV or bleeding event, by treatment group (VKA: VKA Group—NOAC: NOAC Group).

Group	VKA	NOAC	Switch
N of patients	1355	577	239
			VKA+NOAC	Started with VKA	Proceed with NOAC
Effectiveness end-point: CV events
N (%)	198 (14.6%)	57 (9.9%)	43 (18.0%)	32 (13.4%)	14 (5.9%)
P-value¥	-	0.0049*	0.1788	0.6197	0.0002*
Hazard ratio [95% CI] for comparison vs. VKA alone	1.0	0.9 [0.6–1.2]	1.1 [0.8–1.5]	1.2 [0.8–1.8]	0.5 [0.8–1.5]
P-value from Cox proportional hazards model for comparison vs. VKA alone	-	0.3425	0.5481	0.2773	0.0255
Safety end-point: bleeding
N (%)	154 (11.4%)	32 (5.5%)	26 (10.9%)	17 (7.1%)	10 (4.2%)
P-value¥	-	<0.0001*	0.8265	0.0502	0.0008*
Hazard ratio [95% CI] for comparison vs. VKA alone	1.0	0.6 [0.4–0.9]	0.8 [0.5–1.4]	0.8 [0.5–1.4]	0.5 [0.3–1.0]
P-value from Cox proportional hazards model for comparison vs. VKA alone	-	0.0230	0.3612	0.5084	0.0419

^¥ Pair-wise P-value for comparison vs. VKA

*Statistically significant i.e. p<0,05